Skip to main content
SpringerLink
Log in

Mechanisms of action of intravesical treatment

Effect on the ABH surface antigens of urothelial cells

  • Intravesical Chemotherapy, Bladder Cancer, Blood Group Isoantigen
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Blood group isoantigens can be demonstrated immune-histologically on normal urothelium of the urinary bladder by means of the specific red cell adherence test. In preneoplastic and reactive changes of the urothelium and in dysplasia and carcinoma in situ, there is a loss of these antigens. Ultrastructural investigations of carcinoma in situ demonstrate a loss of normal membrane structures such as tight junctions, desmosomes, and glycocalyx. Of 18 patients with carcinoma in situ of the urinary bladder, 12 achieved tumor remission after topical chemotherapy with doxorubicin hydrochloride. A recurrence of blood group isoantigens was demonstrated in patients who achieved tumor remission. The antigenicity reappears before complete normalization of the urothelium. Ultrastructural investigations demonstrated normalization of cellular membrane structures in the respective biopsies. According to these findings and the current literature, the mechanisms of action of doxorubicin hydrochloride in carcinoma in situ may be due to retardation of cell cycle, cell loss by desquamation, cell death, and decrease of growth fraction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Allred LE, Porter KE (1979) Morphology of normal and transformed cells. In: Hynes RO (ed) Surfaces of normal and malignant cells. Wiley, Chichester, p 21

    Google Scholar 

  2. Alroy J, Teramura K, Miller AW, Pauli BU, Gottesman JE, Franagan M, Davidsohn I, Weinstein RS (1978) Isoantigens A, B and H in urinary bladder carcinomas following radiotherapy. Cancer 41:1739

    Google Scholar 

  3. Bergkvist A, Ljungquist A, Moberger G (1965) Classification of bladder tumours based on the cellular pattern. Preliminary report of a clinical pathological study of 300 cases with a minimum follow-up of eight years. Ann Chir Scand 130:371

    Google Scholar 

  4. Bergman S, Javadpour E (1978) Cell surface antigens A, B or O as indicator of malignant potential in stage A bladder carcinoma: A preliminary report. J Urol 119:49

    Google Scholar 

  5. Blum RH, Carter SK (1974) Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med 80:249

    Google Scholar 

  6. Bonfiglio TA, Feinberg MR (1976) Isoantigen loss in cervical neoplasia. Arch Pathol 100:307

    Google Scholar 

  7. Carlsen SA, Till JE, Ling V (1976) Modulation of membrane drug permeability in Chinese hamster ovary cells. Biochim Biophys Acta 455:900

    Google Scholar 

  8. Carter SK (1975) Adriamycin. A review. J Natl Cancer Inst 55:1265

    Google Scholar 

  9. Dabelsteen E, MacKenzie I (1976) Selective loss of blood group antigens during wound healing. Acta Pathol Microbiol Scand [A] 84:445

    Google Scholar 

  10. Davidsohn I (1972) Early immunological diagnosis and prognosis of carcinoma. Am J Clin Pathol 57:715

    Google Scholar 

  11. Decenzo JM, Howard P, Irish CE (1975) Antigenic deletion and prognosis of patients with stage A transitional cell bladder carcinoma. J Urol 114:874

    Google Scholar 

  12. Dorr RT, Alberts DS (1981) Modulation of experimental doxorubicin skin toxicity by beta-adrenergic compunds. Cancer Res 41:2428

    Google Scholar 

  13. Graham JM (1979) Surface membrane enzymes in neoplasia. In: Hynes RO (ed) Surfaces of normal and malignant cells. Wiley, Chichester, p 199

    Google Scholar 

  14. Gupta RK, Schuster R, Christian WD (1972) Loss of isoantigens A, B and H in prostate. Am J Pathol 70:439

    Google Scholar 

  15. Hakomari SI (1975) Fucolipids and blood group glycolipids in normal and tumor tissue. Prog Biochem Pharmacol 10:167

    Google Scholar 

  16. Holborow EJ, Brown PC, Glynn LE, Hawes MD, Gresham GA, O'Brien TF, Coombs RR (1960) The distribution of the blood group A antigen in human tissues. Br J Exp Pathol 41:430

    Google Scholar 

  17. Jakse G, Hofstädter F (1978) Further experiences with the specific red cell adherence test in bladder cancer. Eur Urol 4:356

    Google Scholar 

  18. Jakse G, Hofstädter F (1983) Investigation of ABH antigenicity of random mucosal biopsies and transitional cell carcinoma of the urinary bladder. Eur Urol (in press)

  19. Jakse G. Hofstädter F, Marberger H (1983) Topical doxorubicin hydrochloride therapy for carcinoma in situ of the urinary bladder: a follow-up. J Urol (in press)

  20. Kessel D (1979) Enhanced glycosylation induced by adriamycin. Mol Pharmacol 16:306

    Google Scholar 

  21. Kessel D, Botteril V, Wodinsky J (1968) Uptake and retention of daunomycin by mouse leukemic cells as factors in drug resistance. Cancer Res 28:938

    Google Scholar 

  22. Lange PH, Limas C, Fraley EE (1978) Tissue blood group antigens and prognostis in low-stage transitional cell carcinoma of the bladder. J Urol 119:52

    Google Scholar 

  23. Mikkelsen RB, Lin PS, Wallach DFH (1977) Interaction of adriamycin with red blood cells: a biochemical and morphological study. J Mol Med 2:33

    Google Scholar 

  24. Murphree SA, Cunningham LS, Hwang KM, Sartorelli AC (1976) Effects of adriamycin on surface properties of sarcoma 180 ascites cells. Biochem Pharmacol 25:1227

    Google Scholar 

  25. Rowley R, Hopkins HA, Looney WB (1982) In vivo tumour-cell proliferation after adriamycin treatment. Br J Cancer 45:429

    Google Scholar 

  26. Schwartz HS, Kanter PM (1975) Cell interactions; determinants of selective toxicity of adriamycin and daunorubicin. Cancer Chemother Rep 6:107

    Google Scholar 

  27. Somberg J, Cagin N, Levitt B (1978) Blockade of tissue uptake of the antineoplastic agent doxorubicin. J Pharmacol Exp Ther 204:226

    Google Scholar 

  28. Szulman AE (1962) The histological distribution of the blood group substances in man as disclosed by immunofluorescence. II. The H antigen and its relation to A and B antigen. J Exp Med 115:977

    Google Scholar 

  29. Weinstein RS, Alroy J, Farrow GM, Miller AW, Davidsohn I (1979) Blood group isoantigen deletion in carcinoma in situ of the urinary bladder. Cancer 43:661

    Google Scholar 

  30. Weinstein RS, Coon J, Alroy J, Davidsohn I (1981) Tissue associated blood group antigens in human tumors. In: DeLellis RA (ed) Diagnostic immunohistochemistry. Masson, New York, p 239

    Google Scholar 

  31. Wisniewski S, Knowles JC, Cooper EH (1982) Electron microscopy of superficial bladder tumours and urothelium after intravesical doxorubicin. Eur Urol 8:351

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Innsbruck, Anichstrasse 35, A-6020, Innsbruck, Austria

    Gerhard Jakse & Ferdinand Hofstädter

  2. Institute of Pathology, University of Innsbruck, Anichstrasse 35, A-6020, Innsbruck, Austria

    Gerhard Jakse & Ferdinand Hofstädter

Authors
  1. Gerhard Jakse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ferdinand Hofstädter
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jakse, G., Hofstädter, F. Mechanisms of action of intravesical treatment. Cancer Chemother. Pharmacol. 11 (Suppl 1), S74–S78 (1983). https://doi.org/10.1007/BF00256724

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00256724

Keywords

Search

Navigation